Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients (CAPRI)

Hsue et al., NCT04421404, CAPRI, NCT04421404, Aug 2021

Source

PDF

All
Studies

Meta
Analysis

https://c19early.org/hsue.html

RCT 34 hospitalized patients in the USA, showing no significant difference with convalescent plasma treatment.

Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved. Low-cost treatments were excluded, reducing the probability of treatment—especially early—due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.

Important missing comments or errors? Let us know.

risk of death, 212.5% higher, RR 3.12, p = 0.47, treatment 1 of 16 (6.2%), control 0 of 18 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), day 28.

risk of death, 12.5% higher, RR 1.12, p = 1.00, treatment 1 of 16 (6.2%), control 1 of 18 (5.6%), all cause, day 28.

risk of mechanical ventilation, 425.0% higher, RR 5.25, p = 0.21, treatment 2 of 16 (12.5%), control 0 of 18 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), day 28.

risk of progression, 425.0% higher, RR 5.25, p = 0.21, treatment 2 of 16 (12.5%), control 0 of 18 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), death or mechanical ventilation, day 28, primary outcome.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

1. c19early.org, c19early.org/soc/usa.html.c19early.org/soc/usa.html.

Hsue et al., 23 Aug 2021, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, study period 9 June, 2020 - 30 April, 2021, trial NCT04421404 (history) (CAPRI).

This Paper Conv. Plasma All

Late treatment
is less effective

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0